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A B S T R A C T
The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 
(COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients 
with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical 
trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocili-
zumab at our academic medical center. We report their early clinical outcomes and describe the process by which 
we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time 
of clinical uncertainty.   
The use of unproven therapeutics in a pandemic presents a challenge 
to evidence-based clinical decision making. In the early months, limited 
evidence was available to guide treatment of coronavirus disease 2019 
(COVID-19), caused by the novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Many unproven therapeutics were given to 
patients worldwide, in an effort to find treatments that would improve 
patients’ clinical course and decrease mortality. Without an evidence 
base for a novel disease, clinicians have one of three options: liberally 
treat patients based on small, preliminary case series; withhold un-
proven therapeutics until randomized clinical trial (RCT) results are 
available; or pair initial off-label treatment with rapid analysis of pa-
tients in one’s local practice environment while awaiting RCT results. 
Rapid analysis of off-label tocilizumab use 
We describe our experience with the latter approach for off-label use 
of the interleukin-6 (IL-6) receptor inhibitor tocilizumab in severe 
COVID-19 early in the pandemic. Tocilizumab had been posited to 
reduce the severity of COVID-19 caused by an IL-6-mediated hyper-
inflammatory state based on limited observational studies from China 
and other sites early in the pandemic.1–6 Given the paucity of data on 
tocilizumab use in COVID-19 in the United States early on, and with 
results from randomized controlled trials (RCTs) still months away, we 
performed a rapid, descriptive analysis of the first 11 patients treated 
with off-label tocilizumab for COVID-19 and used the results to guide 
clinical practice at our medical center. 
We repurposed a group of trainees who had been sidelined by the 
COVID-19 pandemic to conduct a rapid-turnaround analysis of tocili-
zumab use at our medical center. As classes and clinical rotations had 
been put on hold, a large pool of trainees with different skill sets were 
available, including graduate students in epidemiology, medical stu-
dents, medical residents, and fellows in infectious diseases. Covariates of 
interest were identified by crowdsourcing to faculty in the UNC divisions 
of infectious diseases, hospital medicine, and pulmonary and critical 
care and the UNC Eshelman School of Pharmacy via email and web 
conference; final data fields were determined by consensus. All trainees 
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the assay’s LOD (≤5 pg/mL) and another of 10.4 pg/mL. Four of five 
with available IL-6 levels after tocilizumab had IL-6 levels above the 
upper limit of quantification. IL-6 increased after tocilizumab in all four 
patients with matched baseline and post-tocilizumab testing. IL-6 levels 
required several days to return and were not available to guide decisions 
about tocilizumab use. 
CRP and fibrinogen decreased significantly after tocilizumab 
(Fig. 2A). Other laboratory markers did not show clear trends (Fig. 2B). 
Temperature did not show obvious improvement (Fig. 2C), and only 
three patients (27%) showed improvement in oxygen requirements 
(Fig. 2D). At end of follow-up, patients were observed for a median of 17 
days (range=7–34) after initial tocilizumab dose. Three died; five 
remained in the intensive care unit (ICU) on mechanical ventilation, 
receiving vasopressors or hemodialysis; one was transferred from the 
ICU to floor status and weaned to room air; and two were discharged 
home without oxygen. No serious adverse events were observed. 
Applying results to clinical practice 
Using an interdisciplinary group of faculty and trainees, we per-
formed a rapid descriptive analysis of patients with COVID-19 treated 
with tocilizumab at our academic medical center, almost all of whom 
required ICU care. While tocilizumab was described as a promising 
therapy for severe COVID-19, our initial descriptive analysis raised 
questions about the generalizability of early observational reports and 
prompted removal from our local treatment algorithms. CRP and 
fibrinogen improved after tocilizumab administration as previously 
reported,1,2,8–10 but improvement in disease severity or mortality was 
not observed. These findings, in addition to low baseline IL-6 levels 
observed in some patients, raised questions about tocilizumab use in 
patients presenting with severe or critical COVID-19. As a result, we 
elected to defer further tocilizumab use until RCT results became 
available. 
Though our cohort was small and our analysis did not include a 
control group, our findings were consistent with signs from early RCTs 
of tocilizumab in COVID-19.11–15 Our findings contrasted with most 
previous observational reports16 and did not provide clear evidence of 
clinical improvement after tocilizumab treatment in patients with severe 
Fig. 1. Timeline of events. The COVID-19 Rapid Practice Improvement Deployment (RaPID) study of tocilizumab successfully extracted, analyzed, and disseminated 
its findings to key stakeholders in less than one week. 
contributed about a month of time and first took an online refresher 
course in research, ethics, and compliance available through the 
Collaborative Institutional Training Initiative (CITI). The study was 
approved by the University of North Carolina at Chapel Hill (UNC) 
Institutional Review Board (IRB), with proactive submission to the IRB 
at the start of the pandemic to enable rapid analysis of local data for 
practice improvement and dissemination of results. After starting data 
extraction, a strict 1-week timeline for extraction, analysis, and 
dissemination was established due to the urgent need for informed 
clinical decision making (Fig. 1). 
We then launched the COVID-19 Rapid Practice Improvement 
Deployment (RaPID) study of tocilizumab, performing a retrospective 
cohort study of patients with COVID-19 treated with tocilizumab at UNC 
Medical Center between March 21st and April 25th, 2020. Clinical data 
was extracted from the medical record. COVID-19 was diagnosed using 
nasopharyngeal swabs and reverse-transcriptase polymerase chain re-
action. IL-6 testing was conducted at Mayo Clinic Laboratories 
(Rochester, MN) using an electrochemiluminescence assay. Baseline IL-6 
values for two patients were from a multi-cytokine panel (lower-limit of 
detection [LOD] of 5.0 pg/mL); all others were from a standalone IL-6 
assay (LOD 1.8 pg/ml). Disease severity was defined according to the 
World Health Organization (WHO) COVID-19 clinical status scale with 
minor modification.7 Descriptive statistics were calculated using JMP 
15. GraphPad Prism 8 was used to test for differences between matched 
measures within a patient 1-day pre- and 5-days post-tolicizumab 
treatment using Wilcoxon signed-rank test. Data were visualized using 
the tidyverse collection of packages in R 3.6.0.
Patient characteristics and early outcomes 
Detailed patient characteristics and early outcomes of the 11 
included patients with confirmed SARS-CoV-2 infection treated with 
tocilizumab are provided in the Supplementary Results and Table. In 
brief, most patients had severe or critical COVID-19 by modified WHO 
criteria at the time of admission. Only three (27%) received corticoste-
roids. Tocilizumab was administered a median of one day (IQR 1–4) 
from admission and nine days (IQR 7–14) after symptom onset. Two of 
six patients with available baseline IL-6 levels had low levels, one below 
COVID-19. We considered several explanations as we recommended 
against routine use of tocilizumab at our medical center. First, our pa-
tients were more severely ill than previous cohorts. It was possible 
tocilizumab was administered too late to offer benefit. Second, our pa-
tient cohort had more comorbidities, notably obesity and hypertension, 
than those in China and Italy, which could influence pathobiology and 
response to treatment. Our cohort was also more racially and ethnically 
diverse, which could reflect differences in baseline healthcare access and 
social determinants of health17 that confound treatment response within 
a small observational sample. Third, improvements observed in prior, 
less severely ill cohorts, might have occurred as part of the natural 
disease process, with or without tocilizumab. While the descriptive na-
ture of our study and its small sample size were insufficient to define 
tocilizumab’s role in the treatment of COVID-19, our findings provided a 
counterpoint to a growing number of small observational studies and 
supported our decision to defer further tocilizumab use while waiting for 
results from rigorous RCTs. 
Rapid dissemination of results to local and external stakeholders 
Data extraction, analysis, and dissemination was performed over the 
course of a single week. Two medical students extracted data, with 
arbitration by an infectious diseases fellow and faculty as needed. Data 
was visualized by an epidemiology graduate student. Initial results were 
presented as part of an interdisciplinary meeting including both pul-
monary and critical care and infectious diseases faculty. Consensus was 
reached to remove tocilizumab from routine clinical practice until RCT 
results became available. Results of the RaPID descriptive analysis of 
tocilizumab, which contrasted with previously published observational 
data, were disseminated externally via immediate pre-print publication 
Fig. 2. Laboratory and clinical outcome data presented to key stakeholders. (A–B) Laboratory trends in eleven COVID-19 patients after tocilizumab treatment. 
Medians (blue lines), interquartile ranges (IQR, blue shading), and reference ranges (dashed red lines). (C–D) Oxygen requirements and temperature trends, displayed 
using locally estimated scatterplot smoothing (orange lines). Patient #6 was treated with two doses of tocilizumab; time 0 refers to the time of initial administration. 
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org/10.1016/j.hjdsi.2021.100581. 
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on medRxiv,18 local news outlets, and via Twitter. 
Implications of available evidence and current guidelines 
The conclusions of our analysis were consistent with early RCT re-
sults, which did not show clear evidence of efficacy in COVID-19 
pneumonia.19 However, more recent RCTs demonstrated a mortality 
benefit when tocilizumab is administered in combination with cortico-
steroids and using specific clinical criteria.20,21 In response, we later 
resumed tocilizumab use for COVID-19 in our hospital in accordance 
with revised U.S. Department of Health and Human Services guide-
lines.22 These guidelines support the use of tocilizumab in combination 
with dexamethasone for select hospitalized patients exhibiting respira-
tory decompensation. This evidence-based approach differs from our 
early ad hoc usage of tocilizumab in critically ill patients with progres-
sive disease. While an argument can be made that broader use of toci-
lizumab early in the pandemic might have benefited patients, many 
therapeutic candidates promoted early on ultimately failed to demon-
strate efficacy for COVID-19, and some caused harm. This experience 
emphasizes the importance of building clinical algorithms based on RCT 
results. 
Lessons learned 
Our experience highlights the value of rapidly analyzing local data to 
guide clinical decision making, especially when available evidence is 
limited. We encourage the use of local hospital data to inform clinical 
decision-making as a bridge until data from RCTs are available. In this 
case, reflection on local practice was an important step in our hospital’s 
management of severe COVID-19 and empowered clinicians to prioritize 
RCT over observational data whenever possible. Established platforms 
within large academic medical systems are insufficiently nimble for this 
type of rapid assessment early in the pandemic, though efforts to 
strengthen data analysis and sharing, such as the U.S. Department of 
Health and Human Services’ National COVID Cohort Collaborative, are 
now bearing fruit and can be translated to future pandemics. Inclusion of 
trainees across disciplines served both the project and their professional 
development, as it offered experience with retrospective data collection 
and rapid dissemination, as well as mentorship from a broad range of 
collaborators. In a historical moment of disrupted schedules and sys-
tems, efficient collaboration by key stakeholders across research and 
clinical arenas enabled locally informed treatment decision making. We 
highlight the value of rapid analysis of local health system data to inform 
clinical decisions in times of uncertainty. 
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